+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Sale

Ulcerative Colitis Market Research Report by Drug Type (Anti-TNF Biologics, Anti-inflammatory Drugs, and Calcineurin Inhibitors), Disease, Region (Americas, Asia-Pacific, and Europe, Middle East & Africa) - Global Forecast to 2027 - Cumulative Impact of COVID-19

  • PDF Icon

    Report

  • 225 Pages
  • July 2022
  • Region: Global
  • 360iResearch™
  • ID: 4985922
UP TO OFF until Dec 31st 2022
The Global Ulcerative Colitis Market size was estimated at USD 6,250.39 million in 2021, USD 6,821.25 million in 2022, and is projected to grow at a CAGR 9.31% to reach USD 10,662.84 million by 2027.

Market Statistics:


The report provides market sizing and forecast across 7 major currencies - USD, EUR, JPY, GBP, AUD, CAD, and CHF. It helps organization leaders make better decisions when currency exchange data is readily available. In this report, the years 2019 and 2020 are considered as historical years, 2021 as the base year, 2022 as the estimated year, and years from 2023 to 2027 are considered as the forecast period.

Market Segmentation & Coverage:


This research report categorizes the Ulcerative Colitis to forecast the revenues and analyze the trends in each of the following sub-markets:
  • Based on Drug Type, the market was studied across Anti-TNF Biologics, Anti-inflammatory Drugs, Calcineurin Inhibitors, and Immunosuppressant.
  • Based on Disease, the market was studied across Fulminant Colitis, Left-sided Colitis, Pancolitis or Universal Colitis, Proctosigmoiditis, and Ulcerative Proctitis.
  • Based on Region, the market was studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, and Thailand. The Europe, Middle East & Africa is further studied across France, Germany, Italy, Netherlands, Qatar, Russia, Saudi Arabia, South Africa, Spain, United Arab Emirates, and United Kingdom.

Cumulative Impact of COVID-19:


COVID-19 is an incomparable global public health emergency that has affected almost every industry, and the long-term effects are projected to impact the industry growth during the forecast period. Our ongoing research amplifies our research framework to ensure the inclusion of underlying COVID-19 issues and potential paths forward. The report delivers insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecasts, considering the COVID-19 impact on the market.

Cumulative Impact of 2022 Russia Ukraine Conflict:


We continuously monitor and update reports on political and economic uncertainty due to the Russian invasion of Ukraine. Negative impacts are significantly foreseen globally, especially across Eastern Europe, European Union, Eastern & Central Asia, and the United States. This contention has severely affected lives and livelihoods and represents far-reaching disruptions in trade dynamics. The potential effects of ongoing war and uncertainty in Eastern Europe are expected to have an adverse impact on the world economy, with especially long-term harsh effects on Russia.This report uncovers the impact of demand & supply, pricing variants, strategic uptake of vendors, and recommendations for Ulcerative Colitis market considering the current update on the conflict and its global response.

Competitive Strategic Window:


The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies to help the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. It describes the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth during a forecast period.

FPNV Positioning Matrix:


The FPNV Positioning Matrix evaluates and categorizes the vendors in the Ulcerative Colitis Market based on Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.

Market Share Analysis:


The Market Share Analysis offers the analysis of vendors considering their contribution to the overall market. It provides the idea of its revenue generation into the overall market compared to other vendors in the space. It provides insights into how vendors are performing in terms of revenue generation and customer base compared to others. Knowing market share offers an idea of the size and competitiveness of the vendors for the base year. It reveals the market characteristics in terms of accumulation, fragmentation, dominance, and amalgamation traits.

Competitive Scenario:


The Competitive Scenario provides an outlook analysis of the various business growth strategies adopted by the vendors. The news covered in this section deliver valuable thoughts at the different stage while keeping up-to-date with the business and engage stakeholders in the economic debate. The competitive scenario represents press releases or news of the companies categorized into Merger & Acquisition, Agreement, Collaboration, & Partnership, New Product Launch & Enhancement, Investment & Funding, and Award, Recognition, & Expansion. All the news collected help vendor to understand the gaps in the marketplace and competitor’s strength and weakness thereby, providing insights to enhance product and service.

Company Usability Profiles:


The report profoundly explores the recent significant developments by the leading vendors and innovation profiles in the Global Ulcerative Colitis Market, including Abbott Laboratories, AbbVie Inc., Ajinomoto Pharmaceuticals Co., Ltd., AstraZeneca PLC, Bausch Health Companies Inc., BioLineRx Ltd, Boehringer Ingelheim GmbH, Celgene Corporation, Circle33, LLC, Cosmo Pharmaceuticals NV, Eli Lilly and Company, Ferring B.V., GlaxoSmithKline PLC, InDex Pharmaceuticals Holding AB, Johnson & Johnson Services, Inc., Merck & Co., Inc., Mitsubishi Tanabe Pharma Corporation, Novartis International AG, Pfizer Inc., Sanofi SA, Takeda Pharmaceuticals, Teva Pharmaceuticals Ltd, and UCB S.A..

The report provides insights on the following pointers:


1. Market Penetration: Provides comprehensive information on the market offered by the key players
2. Market Development: Provides in-depth information about lucrative emerging markets and analyze penetration across mature segments of the markets
3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments
4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players
5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments

The report answers questions such as:


1. What is the market size and forecast of the Global Ulcerative Colitis Market?
2. What are the inhibiting factors and impact of COVID-19 shaping the Global Ulcerative Colitis Market during the forecast period?
3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Ulcerative Colitis Market?
4. What is the competitive strategic window for opportunities in the Global Ulcerative Colitis Market?
5. What are the technology trends and regulatory frameworks in the Global Ulcerative Colitis Market?
6. What is the market share of the leading vendors in the Global Ulcerative Colitis Market?
7. What modes and strategic moves are considered suitable for entering the Global Ulcerative Colitis Market?
Frequently Asked Questions about the Global Ulcerative Colitis Market

What is the estimated value of the Global Ulcerative Colitis Market?

The Global Ulcerative Colitis Market was estimated to be valued at $6250.39 Million in 2021.

What is the growth rate of the Global Ulcerative Colitis Market?

The growth rate of the Global Ulcerative Colitis Market is 9.3%, with an estimated value of $10662.84 Million by 2027.

What is the forecasted size of the Global Ulcerative Colitis Market?

The Global Ulcerative Colitis Market is estimated to be worth $10662.84 Million by 2027.

Who are the key companies in the Global Ulcerative Colitis Market?

Key companies in the Global Ulcerative Colitis Market include Abbott Laboratories, AbbVie Inc., Ajinomoto Pharmaceuticals Co., Ltd., AstraZeneca PLC, Bausch Health Companies Inc., BioLineRx Ltd, Boehringer Ingelheim GmbH, Celgene Corporation and Cosmo Pharmaceuticals NV.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary4. Market Overview
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Rising Incidence of Ulcerative Colitis Globally
5.1.1.2. Robust Availability of Healthcare Facilities and Evolving Drug Development Sector
5.1.1.3. Availability of Patient Assistance Programs and Reimbursement Policies
5.1.2. Restraints
5.1.2.1. Rise in Patent Expiry of Drugs
5.1.3. Opportunities
5.1.3.1. Ongoing Research and Development in the Production of Novel Drugs
5.1.3.2. Increasing Public and Private Organization Involvement in Research of Biologics
5.1.4. Challenges
5.1.4.1. Strict Government Mandates in Approval of Biosimilars
5.2. Cumulative Impact of COVID-19
6. Ulcerative Colitis Market, by Drug Type
6.1. Introduction
6.2. Anti-Tnf Biologics
6.3. Anti-Inflammatory Drugs
6.4. Calcineurin Inhibitors
6.5. Immunosuppressant
7. Ulcerative Colitis Market, by Disease
7.1. Introduction
7.2. Fulminant Colitis
7.3. Left-Sided Colitis
7.4. Pancolitis or Universal Colitis
7.5. Proctosigmoiditis
7.6. Ulcerative Proctitis
8. Americas Ulcerative Colitis Market
8.1. Introduction
8.2. Argentina
8.3. Brazil
8.4. Canada
8.5. Mexico
8.6. United States
9. Asia-Pacific Ulcerative Colitis Market
9.1. Introduction
9.2. Australia
9.3. China
9.4. India
9.5. Indonesia
9.6. Japan
9.7. Malaysia
9.8. Philippines
9.9. Singapore
9.10. South Korea
9.11. Taiwan
9.12. Thailand
10. Europe, Middle East & Africa Ulcerative Colitis Market
10.1. Introduction
10.2. France
10.3. Germany
10.4. Italy
10.5. Netherlands
10.6. Qatar
10.7. Russia
10.8. Saudi Arabia
10.9. South Africa
10.10. Spain
10.11. United Arab Emirates
10.12. United Kingdom
11. Competitive Landscape
11.1. Fpnv Positioning Matrix
11.1.1. Quadrants
11.1.2. Business Strategy
11.1.3. Product Satisfaction
11.2. Market Ranking Analysis
11.3. Market Share Analysis, by Key Player
11.4. Competitive Scenario
11.4.1. Merger & Acquisition
11.4.2. Agreement, Collaboration, & Partnership
11.4.3. New Product Launch & Enhancement
11.4.4. Investment & Funding
11.4.5. Award, Recognition, & Expansion
12. Company Usability Profiles
12.1. Abbott Laboratories
12.2. Abbvie Inc.
12.3. Ajinomoto Pharmaceuticals Co., Ltd.
12.4. Astrazeneca plc
12.5. Bausch Health Companies Inc.
12.6. Biolinerx Ltd
12.7. Boehringer Ingelheim GmbH
12.8. Celgene Corporation
12.9. Circle33, LLC
12.10. Cosmo Pharmaceuticals Nv
12.11. Eli Lilly and Company
12.12. Ferring B.V.
12.13. GlaxoSmithKline plc
12.14. Index Pharmaceuticals Holding Ab
12.15. Johnson & Johnson Services, Inc.
12.16. Merck & Co., Inc.
12.17. Mitsubishi Tanabe Pharma Corporation
12.18. Novartis International Ag
12.19. Pfizer Inc.
12.20. Sanofi Sa
12.21. Takeda Pharmaceuticals
12.22. Teva Pharmaceuticals Ltd
12.23. Ucb S.A.
13. Appendix
13.1. Discussion Guide
13.2. License & Pricing
List of Figures
FIGURE 1. GLOBAL ULCERATIVE COLITIS MARKET: RESEARCH PROCESS
FIGURE 2. GLOBAL ULCERATIVE COLITIS MARKET SIZE, 2021 VS 2027 (USD MILLION)
FIGURE 3. GLOBAL ULCERATIVE COLITIS MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 4. GLOBAL ULCERATIVE COLITIS MARKET SIZE, BY REGION, 2021 VS 2027 (%)
FIGURE 5. GLOBAL ULCERATIVE COLITIS MARKET SIZE, BY REGION, 2021 VS 2027 (USD MILLION)
FIGURE 6. COMPETITIVE STRATEGIC WINDOW FOR GLOBAL ULCERATIVE COLITIS MARKET SIZE, BY REGION, 2027
FIGURE 7. GLOBAL ULCERATIVE COLITIS MARKET DYNAMICS
FIGURE 8. GLOBAL ULCERATIVE COLITIS MARKET SIZE, BY DRUG TYPE, 2021 VS 2027 (%)
FIGURE 9. GLOBAL ULCERATIVE COLITIS MARKET SIZE, BY DRUG TYPE, 2021 VS 2027 (USD MILLION)
FIGURE 10. COMPETITIVE STRATEGIC WINDOW FOR GLOBAL ULCERATIVE COLITIS MARKET SIZE, BY DRUG TYPE, 2027
FIGURE 11. GLOBAL ULCERATIVE COLITIS MARKET SIZE, BY ANTI-TNF BIOLOGICS, 2019-2027 (USD MILLION)
FIGURE 12. GLOBAL ULCERATIVE COLITIS MARKET SIZE, BY ANTI-TNF BIOLOGICS, BY REGION, 2021 VS 2027 (USD MILLION)
FIGURE 13. GLOBAL ULCERATIVE COLITIS MARKET SIZE, BY ANTI-INFLAMMATORY DRUGS, 2019-2027 (USD MILLION)
FIGURE 14. GLOBAL ULCERATIVE COLITIS MARKET SIZE, BY ANTI-INFLAMMATORY DRUGS, BY REGION, 2021 VS 2027 (USD MILLION)
FIGURE 15. GLOBAL ULCERATIVE COLITIS MARKET SIZE, BY CALCINEURIN INHIBITORS, 2019-2027 (USD MILLION)
FIGURE 16. GLOBAL ULCERATIVE COLITIS MARKET SIZE, BY CALCINEURIN INHIBITORS, BY REGION, 2021 VS 2027 (USD MILLION)
FIGURE 17. GLOBAL ULCERATIVE COLITIS MARKET SIZE, BY IMMUNOSUPPRESSANT, 2019-2027 (USD MILLION)
FIGURE 18. GLOBAL ULCERATIVE COLITIS MARKET SIZE, BY IMMUNOSUPPRESSANT, BY REGION, 2021 VS 2027 (USD MILLION)
FIGURE 19. GLOBAL ULCERATIVE COLITIS MARKET SIZE, BY DISEASE, 2021 VS 2027 (%)
FIGURE 20. GLOBAL ULCERATIVE COLITIS MARKET SIZE, BY DISEASE, 2021 VS 2027 (USD MILLION)
FIGURE 21. COMPETITIVE STRATEGIC WINDOW FOR GLOBAL ULCERATIVE COLITIS MARKET SIZE, BY DISEASE, 2027
FIGURE 22. GLOBAL ULCERATIVE COLITIS MARKET SIZE, BY FULMINANT COLITIS, 2019-2027 (USD MILLION)
FIGURE 23. GLOBAL ULCERATIVE COLITIS MARKET SIZE, BY FULMINANT COLITIS, BY REGION, 2021 VS 2027 (USD MILLION)
FIGURE 24. GLOBAL ULCERATIVE COLITIS MARKET SIZE, BY LEFT-SIDED COLITIS, 2019-2027 (USD MILLION)
FIGURE 25. GLOBAL ULCERATIVE COLITIS MARKET SIZE, BY LEFT-SIDED COLITIS, BY REGION, 2021 VS 2027 (USD MILLION)
FIGURE 26. GLOBAL ULCERATIVE COLITIS MARKET SIZE, BY PANCOLITIS OR UNIVERSAL COLITIS, 2019-2027 (USD MILLION)
FIGURE 27. GLOBAL ULCERATIVE COLITIS MARKET SIZE, BY PANCOLITIS OR UNIVERSAL COLITIS, BY REGION, 2021 VS 2027 (USD MILLION)
FIGURE 28. GLOBAL ULCERATIVE COLITIS MARKET SIZE, BY PROCTOSIGMOIDITIS, 2019-2027 (USD MILLION)
FIGURE 29. GLOBAL ULCERATIVE COLITIS MARKET SIZE, BY PROCTOSIGMOIDITIS, BY REGION, 2021 VS 2027 (USD MILLION)
FIGURE 30. GLOBAL ULCERATIVE COLITIS MARKET SIZE, BY ULCERATIVE PROCTITIS, 2019-2027 (USD MILLION)
FIGURE 31. GLOBAL ULCERATIVE COLITIS MARKET SIZE, BY ULCERATIVE PROCTITIS, BY REGION, 2021 VS 2027 (USD MILLION)
FIGURE 32. AMERICAS ULCERATIVE COLITIS MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 33. AMERICAS ULCERATIVE COLITIS MARKET SIZE, BY COUNTRY, 2021 VS 2027 (%)
FIGURE 34. AMERICAS ULCERATIVE COLITIS MARKET SIZE, BY COUNTRY, 2021 VS 2027 (USD MILLION)
FIGURE 35. COMPETITIVE STRATEGIC WINDOW FOR AMERICAS ULCERATIVE COLITIS MARKET SIZE, BY COUNTRY, 2027
FIGURE 36. ARGENTINA ULCERATIVE COLITIS MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 37. BRAZIL ULCERATIVE COLITIS MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 38. CANADA ULCERATIVE COLITIS MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 39. MEXICO ULCERATIVE COLITIS MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 40. UNITED STATES ULCERATIVE COLITIS MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 41. UNITED STATES ULCERATIVE COLITIS MARKET SIZE, BY STATE, 2021 VS 2027 (%)
FIGURE 42. UNITED STATES ULCERATIVE COLITIS MARKET SIZE, BY STATE, 2021 VS 2027 (USD MILLION)
FIGURE 43. COMPETITIVE STRATEGIC WINDOW FOR UNITED STATES ULCERATIVE COLITIS MARKET SIZE, BY STATE, 2027
FIGURE 44. ASIA-PACIFIC ULCERATIVE COLITIS MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 45. ASIA-PACIFIC ULCERATIVE COLITIS MARKET SIZE, BY COUNTRY, 2021 VS 2027 (%)
FIGURE 46. ASIA-PACIFIC ULCERATIVE COLITIS MARKET SIZE, BY COUNTRY, 2021 VS 2027 (USD MILLION)
FIGURE 47. COMPETITIVE STRATEGIC WINDOW FOR ASIA-PACIFIC ULCERATIVE COLITIS MARKET SIZE, BY COUNTRY, 2027
FIGURE 48. AUSTRALIA ULCERATIVE COLITIS MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 49. CHINA ULCERATIVE COLITIS MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 50. INDIA ULCERATIVE COLITIS MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 51. INDONESIA ULCERATIVE COLITIS MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 52. JAPAN ULCERATIVE COLITIS MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 53. MALAYSIA ULCERATIVE COLITIS MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 54. PHILIPPINES ULCERATIVE COLITIS MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 55. SINGAPORE ULCERATIVE COLITIS MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 56. SOUTH KOREA ULCERATIVE COLITIS MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 57. TAIWAN ULCERATIVE COLITIS MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 58. THAILAND ULCERATIVE COLITIS MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 59. EUROPE, MIDDLE EAST & AFRICA ULCERATIVE COLITIS MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 60. EUROPE, MIDDLE EAST & AFRICA ULCERATIVE COLITIS MARKET SIZE, BY COUNTRY, 2021 VS 2027 (%)
FIGURE 61. EUROPE, MIDDLE EAST & AFRICA ULCERATIVE COLITIS MARKET SIZE, BY COUNTRY, 2021 VS 2027 (USD MILLION)
FIGURE 62. COMPETITIVE STRATEGIC WINDOW FOR EUROPE, MIDDLE EAST & AFRICA ULCERATIVE COLITIS MARKET SIZE, BY COUNTRY, 2027
FIGURE 63. FRANCE ULCERATIVE COLITIS MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 64. GERMANY ULCERATIVE COLITIS MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 65. ITALY ULCERATIVE COLITIS MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 66. NETHERLANDS ULCERATIVE COLITIS MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 67. QATAR ULCERATIVE COLITIS MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 68. RUSSIA ULCERATIVE COLITIS MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 69. SAUDI ARABIA ULCERATIVE COLITIS MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 70. SOUTH AFRICA ULCERATIVE COLITIS MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 71. SPAIN ULCERATIVE COLITIS MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 72. UNITED ARAB EMIRATES ULCERATIVE COLITIS MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 73. UNITED KINGDOM ULCERATIVE COLITIS MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 74. GLOBAL ULCERATIVE COLITIS MARKET: FPNV POSITIONING MATRIX, 2021
FIGURE 75. GLOBAL ULCERATIVE COLITIS MARKET SHARE, BY KEY PLAYER, 2021
FIGURE 76. COMPETITIVE SCENARIO ANALYSIS IN GLOBAL ULCERATIVE COLITIS MARKET, BY TYPE
List of Tables
TABLE 1. GLOBAL ULCERATIVE COLITIS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2016-2020
TABLE 3. GLOBAL ULCERATIVE COLITIS MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 4. GLOBAL ULCERATIVE COLITIS MARKET SIZE, BY REGION, 2019-2027 (USD MILLION)
TABLE 5. GLOBAL ULCERATIVE COLITIS MARKET SIZE, BY DRUG TYPE, 2019-2027 (USD MILLION)
TABLE 6. GLOBAL ULCERATIVE COLITIS MARKET SIZE, BY ANTI-TNF BIOLOGICS, BY REGION, 2019-2027 (USD MILLION)
TABLE 7. AMERICAS ULCERATIVE COLITIS MARKET SIZE, BY ANTI-TNF BIOLOGICS, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 8. UNITED STATES ULCERATIVE COLITIS MARKET SIZE, BY ANTI-TNF BIOLOGICS, BY STATE, 2019-2027 (USD MILLION)
TABLE 9. ASIA-PACIFIC ULCERATIVE COLITIS MARKET SIZE, BY ANTI-TNF BIOLOGICS, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 10. EUROPE, MIDDLE EAST & AFRICA ULCERATIVE COLITIS MARKET SIZE, BY ANTI-TNF BIOLOGICS, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 11. GLOBAL ULCERATIVE COLITIS MARKET SIZE, BY ANTI-INFLAMMATORY DRUGS, BY REGION, 2019-2027 (USD MILLION)
TABLE 12. AMERICAS ULCERATIVE COLITIS MARKET SIZE, BY ANTI-INFLAMMATORY DRUGS, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 13. UNITED STATES ULCERATIVE COLITIS MARKET SIZE, BY ANTI-INFLAMMATORY DRUGS, BY STATE, 2019-2027 (USD MILLION)
TABLE 14. ASIA-PACIFIC ULCERATIVE COLITIS MARKET SIZE, BY ANTI-INFLAMMATORY DRUGS, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 15. EUROPE, MIDDLE EAST & AFRICA ULCERATIVE COLITIS MARKET SIZE, BY ANTI-INFLAMMATORY DRUGS, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 16. GLOBAL ULCERATIVE COLITIS MARKET SIZE, BY CALCINEURIN INHIBITORS, BY REGION, 2019-2027 (USD MILLION)
TABLE 17. AMERICAS ULCERATIVE COLITIS MARKET SIZE, BY CALCINEURIN INHIBITORS, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 18. UNITED STATES ULCERATIVE COLITIS MARKET SIZE, BY CALCINEURIN INHIBITORS, BY STATE, 2019-2027 (USD MILLION)
TABLE 19. ASIA-PACIFIC ULCERATIVE COLITIS MARKET SIZE, BY CALCINEURIN INHIBITORS, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 20. EUROPE, MIDDLE EAST & AFRICA ULCERATIVE COLITIS MARKET SIZE, BY CALCINEURIN INHIBITORS, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 21. GLOBAL ULCERATIVE COLITIS MARKET SIZE, BY IMMUNOSUPPRESSANT, BY REGION, 2019-2027 (USD MILLION)
TABLE 22. AMERICAS ULCERATIVE COLITIS MARKET SIZE, BY IMMUNOSUPPRESSANT, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 23. UNITED STATES ULCERATIVE COLITIS MARKET SIZE, BY IMMUNOSUPPRESSANT, BY STATE, 2019-2027 (USD MILLION)
TABLE 24. ASIA-PACIFIC ULCERATIVE COLITIS MARKET SIZE, BY IMMUNOSUPPRESSANT, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 25. EUROPE, MIDDLE EAST & AFRICA ULCERATIVE COLITIS MARKET SIZE, BY IMMUNOSUPPRESSANT, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 26. GLOBAL ULCERATIVE COLITIS MARKET SIZE, BY DISEASE, 2019-2027 (USD MILLION)
TABLE 27. GLOBAL ULCERATIVE COLITIS MARKET SIZE, BY FULMINANT COLITIS, BY REGION, 2019-2027 (USD MILLION)
TABLE 28. AMERICAS ULCERATIVE COLITIS MARKET SIZE, BY FULMINANT COLITIS, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 29. UNITED STATES ULCERATIVE COLITIS MARKET SIZE, BY FULMINANT COLITIS, BY STATE, 2019-2027 (USD MILLION)
TABLE 30. ASIA-PACIFIC ULCERATIVE COLITIS MARKET SIZE, BY FULMINANT COLITIS, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 31. EUROPE, MIDDLE EAST & AFRICA ULCERATIVE COLITIS MARKET SIZE, BY FULMINANT COLITIS, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 32. GLOBAL ULCERATIVE COLITIS MARKET SIZE, BY LEFT-SIDED COLITIS, BY REGION, 2019-2027 (USD MILLION)
TABLE 33. AMERICAS ULCERATIVE COLITIS MARKET SIZE, BY LEFT-SIDED COLITIS, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 34. UNITED STATES ULCERATIVE COLITIS MARKET SIZE, BY LEFT-SIDED COLITIS, BY STATE, 2019-2027 (USD MILLION)
TABLE 35. ASIA-PACIFIC ULCERATIVE COLITIS MARKET SIZE, BY LEFT-SIDED COLITIS, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 36. EUROPE, MIDDLE EAST & AFRICA ULCERATIVE COLITIS MARKET SIZE, BY LEFT-SIDED COLITIS, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 37. GLOBAL ULCERATIVE COLITIS MARKET SIZE, BY PANCOLITIS OR UNIVERSAL COLITIS, BY REGION, 2019-2027 (USD MILLION)
TABLE 38. AMERICAS ULCERATIVE COLITIS MARKET SIZE, BY PANCOLITIS OR UNIVERSAL COLITIS, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 39. UNITED STATES ULCERATIVE COLITIS MARKET SIZE, BY PANCOLITIS OR UNIVERSAL COLITIS, BY STATE, 2019-2027 (USD MILLION)
TABLE 40. ASIA-PACIFIC ULCERATIVE COLITIS MARKET SIZE, BY PANCOLITIS OR UNIVERSAL COLITIS, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 41. EUROPE, MIDDLE EAST & AFRICA ULCERATIVE COLITIS MARKET SIZE, BY PANCOLITIS OR UNIVERSAL COLITIS, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 42. GLOBAL ULCERATIVE COLITIS MARKET SIZE, BY PROCTOSIGMOIDITIS, BY REGION, 2019-2027 (USD MILLION)
TABLE 43. AMERICAS ULCERATIVE COLITIS MARKET SIZE, BY PROCTOSIGMOIDITIS, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 44. UNITED STATES ULCERATIVE COLITIS MARKET SIZE, BY PROCTOSIGMOIDITIS, BY STATE, 2019-2027 (USD MILLION)
TABLE 45. ASIA-PACIFIC ULCERATIVE COLITIS MARKET SIZE, BY PROCTOSIGMOIDITIS, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 46. EUROPE, MIDDLE EAST & AFRICA ULCERATIVE COLITIS MARKET SIZE, BY PROCTOSIGMOIDITIS, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 47. GLOBAL ULCERATIVE COLITIS MARKET SIZE, BY ULCERATIVE PROCTITIS, BY REGION, 2019-2027 (USD MILLION)
TABLE 48. AMERICAS ULCERATIVE COLITIS MARKET SIZE, BY ULCERATIVE PROCTITIS, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 49. UNITED STATES ULCERATIVE COLITIS MARKET SIZE, BY ULCERATIVE PROCTITIS, BY STATE, 2019-2027 (USD MILLION)
TABLE 50. ASIA-PACIFIC ULCERATIVE COLITIS MARKET SIZE, BY ULCERATIVE PROCTITIS, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 51. EUROPE, MIDDLE EAST & AFRICA ULCERATIVE COLITIS MARKET SIZE, BY ULCERATIVE PROCTITIS, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 52. AMERICAS ULCERATIVE COLITIS MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 53. AMERICAS ULCERATIVE COLITIS MARKET SIZE, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 54. AMERICAS ULCERATIVE COLITIS MARKET SIZE, BY DRUG TYPE, 2019-2027 (USD MILLION)
TABLE 55. AMERICAS ULCERATIVE COLITIS MARKET SIZE, BY DISEASE, 2019-2027 (USD MILLION)
TABLE 56. ARGENTINA ULCERATIVE COLITIS MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 57. ARGENTINA ULCERATIVE COLITIS MARKET SIZE, BY DRUG TYPE, 2019-2027 (USD MILLION)
TABLE 58. ARGENTINA ULCERATIVE COLITIS MARKET SIZE, BY DISEASE, 2019-2027 (USD MILLION)
TABLE 59. BRAZIL ULCERATIVE COLITIS MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 60. BRAZIL ULCERATIVE COLITIS MARKET SIZE, BY DRUG TYPE, 2019-2027 (USD MILLION)
TABLE 61. BRAZIL ULCERATIVE COLITIS MARKET SIZE, BY DISEASE, 2019-2027 (USD MILLION)
TABLE 62. CANADA ULCERATIVE COLITIS MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 63. CANADA ULCERATIVE COLITIS MARKET SIZE, BY DRUG TYPE, 2019-2027 (USD MILLION)
TABLE 64. CANADA ULCERATIVE COLITIS MARKET SIZE, BY DISEASE, 2019-2027 (USD MILLION)
TABLE 65. MEXICO ULCERATIVE COLITIS MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 66. MEXICO ULCERATIVE COLITIS MARKET SIZE, BY DRUG TYPE, 2019-2027 (USD MILLION)
TABLE 67. MEXICO ULCERATIVE COLITIS MARKET SIZE, BY DISEASE, 2019-2027 (USD MILLION)
TABLE 68. UNITED STATES ULCERATIVE COLITIS MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 69. UNITED STATES ULCERATIVE COLITIS MARKET SIZE, BY STATE, 2019-2027 (USD MILLION)
TABLE 70. UNITED STATES ULCERATIVE COLITIS MARKET SIZE, BY DRUG TYPE, 2019-2027 (USD MILLION)
TABLE 71. UNITED STATES ULCERATIVE COLITIS MARKET SIZE, BY DISEASE, 2019-2027 (USD MILLION)
TABLE 72. ASIA-PACIFIC ULCERATIVE COLITIS MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 73. ASIA-PACIFIC ULCERATIVE COLITIS MARKET SIZE, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 74. ASIA-PACIFIC ULCERATIVE COLITIS MARKET SIZE, BY DRUG TYPE, 2019-2027 (USD MILLION)
TABLE 75. ASIA-PACIFIC ULCERATIVE COLITIS MARKET SIZE, BY DISEASE, 2019-2027 (USD MILLION)
TABLE 76. AUSTRALIA ULCERATIVE COLITIS MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 77. AUSTRALIA ULCERATIVE COLITIS MARKET SIZE, BY DRUG TYPE, 2019-2027 (USD MILLION)
TABLE 78. AUSTRALIA ULCERATIVE COLITIS MARKET SIZE, BY DISEASE, 2019-2027 (USD MILLION)
TABLE 79. CHINA ULCERATIVE COLITIS MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 80. CHINA ULCERATIVE COLITIS MARKET SIZE, BY DRUG TYPE, 2019-2027 (USD MILLION)
TABLE 81. CHINA ULCERATIVE COLITIS MARKET SIZE, BY DISEASE, 2019-2027 (USD MILLION)
TABLE 82. INDIA ULCERATIVE COLITIS MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 83. INDIA ULCERATIVE COLITIS MARKET SIZE, BY DRUG TYPE, 2019-2027 (USD MILLION)
TABLE 84. INDIA ULCERATIVE COLITIS MARKET SIZE, BY DISEASE, 2019-2027 (USD MILLION)
TABLE 85. INDONESIA ULCERATIVE COLITIS MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 86. INDONESIA ULCERATIVE COLITIS MARKET SIZE, BY DRUG TYPE, 2019-2027 (USD MILLION)
TABLE 87. INDONESIA ULCERATIVE COLITIS MARKET SIZE, BY DISEASE, 2019-2027 (USD MILLION)
TABLE 88. JAPAN ULCERATIVE COLITIS MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 89. JAPAN ULCERATIVE COLITIS MARKET SIZE, BY DRUG TYPE, 2019-2027 (USD MILLION)
TABLE 90. JAPAN ULCERATIVE COLITIS MARKET SIZE, BY DISEASE, 2019-2027 (USD MILLION)
TABLE 91. MALAYSIA ULCERATIVE COLITIS MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 92. MALAYSIA ULCERATIVE COLITIS MARKET SIZE, BY DRUG TYPE, 2019-2027 (USD MILLION)
TABLE 93. MALAYSIA ULCERATIVE COLITIS MARKET SIZE, BY DISEASE, 2019-2027 (USD MILLION)
TABLE 94. PHILIPPINES ULCERATIVE COLITIS MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 95. PHILIPPINES ULCERATIVE COLITIS MARKET SIZE, BY DRUG TYPE, 2019-2027 (USD MILLION)
TABLE 96. PHILIPPINES ULCERATIVE COLITIS MARKET SIZE, BY DISEASE, 2019-2027 (USD MILLION)
TABLE 97. SINGAPORE ULCERATIVE COLITIS MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 98. SINGAPORE ULCERATIVE COLITIS MARKET SIZE, BY DRUG TYPE, 2019-2027 (USD MILLION)
TABLE 99. SINGAPORE ULCERATIVE COLITIS MARKET SIZE, BY DISEASE, 2019-2027 (USD MILLION)
TABLE 100. SOUTH KOREA ULCERATIVE COLITIS MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 101. SOUTH KOREA ULCERATIVE COLITIS MARKET SIZE, BY DRUG TYPE, 2019-2027 (USD MILLION)
TABLE 102. SOUTH KOREA ULCERATIVE COLITIS MARKET SIZE, BY DISEASE, 2019-2027 (USD MILLION)
TABLE 103. TAIWAN ULCERATIVE COLITIS MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 104. TAIWAN ULCERATIVE COLITIS MARKET SIZE, BY DRUG TYPE, 2019-2027 (USD MILLION)
TABLE 105. TAIWAN ULCERATIVE COLITIS MARKET SIZE, BY DISEASE, 2019-2027 (USD MILLION)
TABLE 106. THAILAND ULCERATIVE COLITIS MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 107. THAILAND ULCERATIVE COLITIS MARKET SIZE, BY DRUG TYPE, 2019-2027 (USD MILLION)
TABLE 108. THAILAND ULCERATIVE COLITIS MARKET SIZE, BY DISEASE, 2019-2027 (USD MILLION)
TABLE 109. EUROPE, MIDDLE EAST & AFRICA ULCERATIVE COLITIS MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 110. EUROPE, MIDDLE EAST & AFRICA ULCERATIVE COLITIS MARKET SIZE, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 111. EUROPE, MIDDLE EAST & AFRICA ULCERATIVE COLITIS MARKET SIZE, BY DRUG TYPE, 2019-2027 (USD MILLION)
TABLE 112. EUROPE, MIDDLE EAST & AFRICA ULCERATIVE COLITIS MARKET SIZE, BY DISEASE, 2019-2027 (USD MILLION)
TABLE 113. FRANCE ULCERATIVE COLITIS MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 114. FRANCE ULCERATIVE COLITIS MARKET SIZE, BY DRUG TYPE, 2019-2027 (USD MILLION)
TABLE 115. FRANCE ULCERATIVE COLITIS MARKET SIZE, BY DISEASE, 2019-2027 (USD MILLION)
TABLE 116. GERMANY ULCERATIVE COLITIS MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 117. GERMANY ULCERATIVE COLITIS MARKET SIZE, BY DRUG TYPE, 2019-2027 (USD MILLION)
TABLE 118. GERMANY ULCERATIVE COLITIS MARKET SIZE, BY DISEASE, 2019-2027 (USD MILLION)
TABLE 119. ITALY ULCERATIVE COLITIS MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 120. ITALY ULCERATIVE COLITIS MARKET SIZE, BY DRUG TYPE, 2019-2027 (USD MILLION)
TABLE 121. ITALY ULCERATIVE COLITIS MARKET SIZE, BY DISEASE, 2019-2027 (USD MILLION)
TABLE 122. NETHERLANDS ULCERATIVE COLITIS MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 123. NETHERLANDS ULCERATIVE COLITIS MARKET SIZE, BY DRUG TYPE, 2019-2027 (USD MILLION)
TABLE 124. NETHERLANDS ULCERATIVE COLITIS MARKET SIZE, BY DISEASE, 2019-2027 (USD MILLION)
TABLE 125. QATAR ULCERATIVE COLITIS MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 126. QATAR ULCERATIVE COLITIS MARKET SIZE, BY DRUG TYPE, 2019-2027 (USD MILLION)
TABLE 127. QATAR ULCERATIVE COLITIS MARKET SIZE, BY DISEASE, 2019-2027 (USD MILLION)
TABLE 128. RUSSIA ULCERATIVE COLITIS MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 129. RUSSIA ULCERATIVE COLITIS MARKET SIZE, BY DRUG TYPE, 2019-2027 (USD MILLION)
TABLE 130. RUSSIA ULCERATIVE COLITIS MARKET SIZE, BY DISEASE, 2019-2027 (USD MILLION)
TABLE 131. SAUDI ARABIA ULCERATIVE COLITIS MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 132. SAUDI ARABIA ULCERATIVE COLITIS MARKET SIZE, BY DRUG TYPE, 2019-2027 (USD MILLION)
TABLE 133. SAUDI ARABIA ULCERATIVE COLITIS MARKET SIZE, BY DISEASE, 2019-2027 (USD MILLION)
TABLE 134. SOUTH AFRICA ULCERATIVE COLITIS MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 135. SOUTH AFRICA ULCERATIVE COLITIS MARKET SIZE, BY DRUG TYPE, 2019-2027 (USD MILLION)
TABLE 136. SOUTH AFRICA ULCERATIVE COLITIS MARKET SIZE, BY DISEASE, 2019-2027 (USD MILLION)
TABLE 137. SPAIN ULCERATIVE COLITIS MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 138. SPAIN ULCERATIVE COLITIS MARKET SIZE, BY DRUG TYPE, 2019-2027 (USD MILLION)
TABLE 139. SPAIN ULCERATIVE COLITIS MARKET SIZE, BY DISEASE, 2019-2027 (USD MILLION)
TABLE 140. UNITED ARAB EMIRATES ULCERATIVE COLITIS MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 141. UNITED ARAB EMIRATES ULCERATIVE COLITIS MARKET SIZE, BY DRUG TYPE, 2019-2027 (USD MILLION)
TABLE 142. UNITED ARAB EMIRATES ULCERATIVE COLITIS MARKET SIZE, BY DISEASE, 2019-2027 (USD MILLION)
TABLE 143. UNITED KINGDOM ULCERATIVE COLITIS MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 144. UNITED KINGDOM ULCERATIVE COLITIS MARKET SIZE, BY DRUG TYPE, 2019-2027 (USD MILLION)
TABLE 145. UNITED KINGDOM ULCERATIVE COLITIS MARKET SIZE, BY DISEASE, 2019-2027 (USD MILLION)
TABLE 146. GLOBAL ULCERATIVE COLITIS MARKET: FPNV POSITIONING MATRIX - SCORES, 2021
TABLE 147. GLOBAL ULCERATIVE COLITIS MARKET: FPNV POSITIONING MATRIX - BUSINESS STRATEGY, 2021
TABLE 148. GLOBAL ULCERATIVE COLITIS MARKET: FPNV POSITIONING MATRIX - PRODUCT SATISFACTION, 2021
TABLE 149. GLOBAL ULCERATIVE COLITIS MARKET RANKING
TABLE 150. GLOBAL ULCERATIVE COLITIS MARKET SHARE, BY KEY PLAYER, 2021
TABLE 151. GLOBAL ULCERATIVE COLITIS MARKET MERGER & ACQUISITION
TABLE 152. GLOBAL ULCERATIVE COLITIS MARKET AGREEMENT, COLLABORATION, & PARTNERSHIP
TABLE 153. GLOBAL ULCERATIVE COLITIS MARKET NEW PRODUCT LAUNCH & ENHANCEMENT
TABLE 154. GLOBAL ULCERATIVE COLITIS MARKET INVESTMENT & FUNDING
TABLE 155. GLOBAL ULCERATIVE COLITIS MARKET AWARD, RECOGNITION, & EXPANSION
TABLE 156. GLOBAL ULCERATIVE COLITIS MARKET: LICENSE & PRICING

Companies Mentioned

  • Abbott Laboratories
  • AbbVie Inc.
  • Ajinomoto Pharmaceuticals Co., Ltd.
  • AstraZeneca PLC
  • Bausch Health Companies Inc.
  • BioLineRx Ltd
  • Boehringer Ingelheim GmbH
  • Celgene Corporation
  • Circle33, LLC
  • Cosmo Pharmaceuticals NV
  • Eli Lilly and Company
  • Ferring B.V.
  • GlaxoSmithKline PLC
  • InDex Pharmaceuticals Holding AB
  • Johnson & Johnson Services, Inc.
  • Merck & Co., Inc.
  • Mitsubishi Tanabe Pharma Corporation
  • Novartis International AG
  • Pfizer Inc.
  • Sanofi SA
  • Takeda Pharmaceuticals
  • Teva Pharmaceuticals Ltd
  • UCB S.A.

Methodology

Loading
LOADING...